Immunotherapy – Page 2

World Cancer Day 2025: Innovations in Prevention, Detection, and Treatment

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Cancer Research, Clinical Trials, Detection, Immunotherapy, Neoplasms, New, Precision Medicine

cancer research, immunotherapy, early detection, AI in oncology, novel therapies, clinical trials, personalized medicine

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

4 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

5 months ago talkbio0Tagged Biotechnology, Immunotherapy, Inflammation, multi-specific antibodies, Neoplasms, Numab, Series C

Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology

Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch

5 months ago talkbio0Tagged Citius Oncology, commercial, Immunotherapy, launch, LYMPHIR, strategic alternatives

Citius Oncology, LYMPHIR, strategic alternatives, commercial launch, cutaneous T-cell lymphoma, immunotherapy

FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications

5 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, hyaluronidase, Immunotherapy, Myers, nivolumab, squibb, Subcutaneous Opdivo, United States Food and Drug Administration

FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase

FDA Approves UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma, Marking a New Era in Skin Cancer Treatment

6 months ago talkbio0Tagged Approved, checkpoint inhibitor, cosibelimab-ipdl, Immunotherapy, Malignant neoplasm of skin, Squamous cell carcinoma, Squamous cell carcinoma of skin, United States Food and Drug Administration, UNLOXCYT

UNLOXCYT, cosibelimab-ipdl, FDA approval, advanced cutaneous squamous cell carcinoma (cSCC), checkpoint inhibitor, immunotherapy, skin cancer treatment.